Review demonstrates GLP-1 receptor agonists improve both quality of life and mortality outcomes, establishing them as multi-benefit therapies beyond blood sugar and weight.
Live better + longerGLP-1 drugs improve quality of life across multiple domains while also reducing mortality — the ultimate patient outcomes
What the researchers found
GLP-1 drugs improve patient-reported quality of life across multiple domains while also reducing all-cause and cardiovascular mortality.
Why it matters
Patients care about feeling better and living longer — not just lab numbers. Demonstrating that GLP-1 drugs deliver on both counts is the strongest possible evidence for their value.
The numbers in context
Primary outcomes: hospitalization events, MACE, mortality. Four databases searched. Quality of life was also assessed.
How the study worked
Review of QoL data from clinical trials and mortality data from cardiovascular outcome trials of GLP-1 receptor agonists.
Who was studied
Heart failure patients with preserved ejection fraction (HFpEF)
What this study cannot tell us
QoL assessment tools vary across trials. Mortality benefits mainly demonstrated in high-cardiovascular-risk populations. Whether mortality reduction extends to lower-risk patients is unclear.
How to read the evidence
Strong evidence: review of clinical trial data including cardiovascular outcome trials with mortality endpoints.
When this study was published
Published in 2025. Synthesizes the most complete QoL and mortality evidence for GLP-1 drugs.
The bigger picture
The shift from glucose-centric to patient-centric diabetes care is complete. GLP-1 drugs deliver on every level: metabolic parameters, organ protection, quality of life, and survival. This positions them as perhaps the most valuable drug class in metabolic medicine.
Questions still open
- Which GLP-1 drug provides the greatest quality of life improvement?
- Do mortality benefits extend to patients without high cardiovascular risk?
- How much of the QoL improvement is from weight loss vs direct drug effects?
Common questions
Do GLP-1 drugs help you live longer?
Will I feel better on a GLP-1 drug?
Read the original research
Glucagon-like peptide-1 receptor agonists for improving quality of life and mortality in adults with heart failure with preserved ejection fraction: A systematic review and meta-analysis of efficacy and safety.
Semergen, 51(9), 102628
Citation
Ahmad, B; Kumar Singh, P; Shah, R J; Hammad Arif, M; Goel, A; Saeed, M; Omar Saleh, A; Amer, S E; Mukhlis, M; Ahmed Waqas, S; Ahmed, R. (2025). Glucagon-like peptide-1 receptor agonists for improving quality of life and mortality in adults with heart failure with preserved ejection fraction: A systematic review and meta-analysis of efficacy and safety.. Semergen, 51(9), 102628. https://doi.org/10.1016/j.semerg.2025.102628